155399-10-3

Usage

Uses

Used in Organic Synthesis:
4-BENZYL-3-PENT-4-ENOYL-1,3-OXAZOLIDIN-2-ONE is used as a synthetic building block for the development of new organic compounds. Its unique structure allows it to be a versatile component in the synthesis of various molecules, making it a valuable asset in the field of organic chemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-BENZYL-3-PENT-4-ENOYL-1,3-OXAZOLIDIN-2-ONE is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique properties and reactivity make it an essential component in the development of new drugs and medications.
Used in Chemical Research:
4-BENZYL-3-PENT-4-ENOYL-1,3-OXAZOLIDIN-2-ONE is also used in chemical research as a model compound to study various chemical reactions and mechanisms. Its unique structure and properties make it an ideal candidate for understanding the behavior of similar compounds and developing new synthetic strategies.
Used in Material Science:
In the field of material science, 4-BENZYL-3-PENT-4-ENOYL-1,3-OXAZOLIDIN-2-ONE can be used as a component in the development of new materials with specific properties. Its unique chemical structure can contribute to the creation of materials with enhanced performance characteristics, such as improved stability, reactivity, or selectivity.

Upstream product

• 591-80-0 pent-4-enoic acid 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 3282-30-2 pivaloyl chloride 
• 178327-16-7 C₄H₇CO₂COC₄H₉ 
• 39716-58-0 pent-4-enoyl chloride 

Downstream Products

• 324741-98-2 (R)-3-((2S,3S)-2-Allyl-3-hydroxy-pent-4-enoyl)-4-benzyl-oxazolidin-2-one 
• 851518-35-9 (S)-tert-butyl 3-((R)-4-benzyl-2-oxooxazolidine-3-carbonyl)hex-5-enoate 
• 1010704-83-2 C₂₅H₂₉NO₅ 
• 955373-72-5 (R)-4-benzyl-3-[(S)-2-(4-benzyloxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-onecf 
• 955406-19-6 (R)-4-Benzyl-3-[(S)-2-(6-chloro-2,3-difluoro-4-trifluoromethyl-benzyl)-pent-4-enoyl]-oxazolidin-2-one 
• 955406-31-2 (R)-4-Benzyl-3-[(S)-2-(4-benzyloxy-2,6-dimethyl-benzyl)-pent-4-enoyl]-oxazolidin-2-one 
• 955406-64-1 (R)-4-Benzyl-3-[(S)-2-(3,5-dichloro-4'-fluoro-biphenyl-4-ylmethyl)-pent-4-enoyl]-oxazolidin-2-one 
• 1201328-77-9 (R)-4-benzyl-3-{(S)-2-[(R)-(hydroxy)(3,4-methylenedioxyphenyl)-methyl]-4-pentenoyl}-2-oxazolidinone 
• 1214939-83-9 C₁₉H₂₃NO₅ 
• 1166991-50-9 C₁₉H₂₃NO₅ 
• 955406-20-9 (R)-4-((R)-4-Benzyl-2-oxo-oxazolidin-3-yl)-3-(6-chloro-2,3-difluoro-4-trifluoromethyl-benzyl)-4-oxo-butyraldehyde 
• 1132653-78-1 (R)-2-((S)-2-(2-(4-chlorobenzylamino)-2-oxoethyl)pent-4-enamido)-1-phenylethyl pent-4-enoate 
• 1192277-16-9 N-((6-chloropyridin-3-yl)methyl)-2-((2R,6S,E)-5,12-dioxo-2-phenyl-1-oxa-4-azacyclododec-8-en-6-yl)acetamide 
• 1192277-45-4 N-(4-chlorobenzyl)-2-((3R,11S,E)-5,12-dioxo-3-phenyl-1-oxa-4-azacyclododec-8-en-11-yl)acetamide 

Relevant academic research and scientific papers

Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route

Stimulator of Interferon Genes (STING) plays an important role in innate immunity by inducing type I interferon production upon infection with intracellular pathogens. STING activation can promote increased T-cell activation and inflammation in the tumor microenvironment, resulting in antitumor immunity. Natural and synthetic cyclic dinucleotides (CDNs) are known to activate STING, and several synthetic CDN molecules are being investigated in the clinic using an intratumoral administration route. Here, we describe the identification of STING agonist 15a, a cyclic dinucleotide structurally diversified from natural ligands with optimized properties for systemic intravenous (iv) administration. Our studies have shown that STING activation by 15a leads to an acute innate immune response as measured by cytokine secretion and adaptive immune response via activation of CD8+ cytotoxic T-cells, which ultimately provides robust antitumor efficacy.

Target-Based Design of Promysalin Analogues Identifies a New Putative Binding Cleft in Succinate Dehydrogenase

Promysalin is a small-molecule natural product that specifically inhibits growth of the Gram-negative pathogen Pseudomonas aeruginosa (PA). This activity holds promise in the treatment of multidrug resistant infections found in immunocompromised patients

STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING

The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity

Histone deacetylase (HDAC) enzymes govern the post-translational acetylation state of lysine residues on protein substrates, leading to regulatory changes in cell function. Due to their role in cancers, HDAC proteins have emerged as promising targets for

Structural requirements of histone deacetylase inhibitors: C4-modified saha analogs display dual HDAC6/HDAC8 selectivity

A compound having formula I for histone deacetylase inhibition is provided: or a pharmaceutically acceptable salt or hydrate thereof wherein R is alkyl, C6-18 aryl, C5-18 heteroaryl, C8-22 alkylaryl, C8-22 alkyl

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Unprecedented 8,9′-neolignans: Enantioselective synthesis of possible stereoisomers for structural determination

(+)-Wutaienin (3) and its C-7 methyl ether (4), isolated from Zanthoxylum wutaiense, were found to be unprecedented 8,9′-neolignans containing an (S)-2-(1,1-dimethyl-1-hydroxymethyl)-7-methoxydihydrobenzofuran skeleton. Wutaienin (3) was present in the pl

Hepatitis C replication inhibitors that target the viral NS4B protein

We describe the preclinical development and in vivo efficacy of a novel chemical series that inhibits hepatitis C virus replication via direct interaction with the viral nonstructural protein 4B (NS4B). Significant potency improvements were realized through isosteric modifications to our initial lead 1a. The temptation to improve antiviral activity while compromising physicochemical properties was tempered by the judicial use of ligand efficiency indices during lead optimization. In this manner, compound 1a was transformed into (+)-28a which possessed an improved antiviral profile with no increase in molecular weight and only a modest elevation in lipophilicity. Additionally, we employed a chimeric "humanized" mouse model of HCV infection to demonstrate for the first time that a small molecule with high in vitro affinity for NS4B can inhibit viral replication in vivo. This successful proof-of-concept study suggests that drugs targeting NS4B may represent a viable treatment option for curing HCV infection.

BENZIMIDAZOLE ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and/or Formula (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).